GALNT13: A Potential Drug Target and Biomarker (G114805)

Target Name: GALNT13

NCBI ID: G114805

GALNT13

Other Name(s): polypeptide N-acetylgalactosaminyltransferase 13 variant deltaEx9 | UDP-N-acetyl-alpha-D-galactosamine:polypeptide N-acetylgalactosaminyltransferase 13 (GalNAc-T13) | UDP-N-acetyl-alpha-D-galactosamine:polypeptide N-acetylgalactosaminyltransferase 13 | polypeptide N-acetylgalactosaminyltransferase 13 variant deltaEx2-7 | FLJ41157 | polypeptide N-acetylgalactosaminyltransferase 13 variant delta39bpEx9 | polypeptide GalNAc transferase 13 | Polypeptide N-acetylgalactosaminyltransferase 13 (isoform 1) | GLT13_HUMAN | Polypeptide N-acetylgalactosaminyltransferase 13 | polypeptide N-acetylgalactosaminyltransferase 13 variant deltaEx6 deltaEx8 delta39bpEx9 | polypeptide N-acetylgalactosaminyltransferase 13 variant deltaEx8 | GalNAc transferase 13 | Polypeptide GalNAc transferase 13 | GALNT13 variant 1 | GalNAc-T13 | pp-GaNTase 13 | Protein-UDP acetylgalactosaminyltransferase 13 | polypeptide N-acetylgalactosaminyltransferase 13 variant deltaEx6 delta39bpEx9 | protein-UDP acetylgalactosaminyltransferase 13 | KIAA1918 | polypeptide N-acetylgalactosaminyltransferase 13 | UDP-GalNAc:polypeptide N-acetylgalactosaminyltransferase 13 | Polypeptide N-acetylgalactosaminyltransferase 13, transcript variant 1

GALNT13: A Potential Drug Target and Biomarker

GALNT13, a variant of the N-acetylgalactosaminyltransferase (Galactose enzyme), is a protein that plays a crucial role in the metabolism of lactose, a sugar found in milk and other dairy products. The primary function of Galactose enzyme is to transfer the N- acetyl group from Galactose to other carbohydrates, thereby modifying their structure and function. GALNT13 is a variant of Galactose enzyme that has a unique substitution in its active site, resulting in the production of a unique protein with altered catalytic properties.

GALNT13 is a glycophosphonate transporter, which means it is involved in the transport of glycophosphonates across cell membranes. In addition to its role in lactose metabolism, GALNT13 is also involved in the regulation of cell signaling pathways, including the TGF-β pathway. This suggests that GALNT13 may be a potential drug target for the treatment of various diseases associated with the TGF-β pathway, such as cancer, neurodegenerative diseases, and autoimmune disorders.

The TGF-β pathway is a complex signaling pathway that plays a crucial role in the development and maintenance of tissues, including muscles, bones, and organs. It is involved in the regulation of cell proliferation, differentiation, and survival, and is often disrupted in diseases such as cancer, neurodegenerative diseases, and autoimmune disorders. The TGF-β pathway is also known for its role in the regulation of cell signaling pathways, including the FGF pathway, which is involved in the regulation of cell growth and differentiation.

GALNT13 has been shown to play a crucial role in the regulation of the TGF-β pathway. It is a key component of the TGF-β complex, which is responsible for the regulation of cell proliferation and differentiation. GALNT13 has been shown to function as a negative regulator of the TGF-β complex, limiting the activity of the active forms of TGF-β. This unique function of GALNT13 makes it an attractive drug target for the treatment of diseases associated with the TGF-β pathway.

In addition to its role in the TGF-β pathway, GALNT13 has also been shown to play a crucial role in the regulation of cell signaling pathways, including the FGF pathway. GALNT13 has been shown to function as a negative regulator of the FGF pathway, limiting the activity of the active forms of FGF. This suggests that GALNT13 may be a potential drug target for the treatment of diseases associated with the FGF pathway, such as cancer and neurodegenerative diseases.

GALNT13 is also involved in the regulation of cell signaling pathways that are not related to the TGF-β or FGF pathways. For example, GALNT13 has been shown to play a role in the regulation of cell signaling pathways that are involved in the regulation of cell adhesion, migration, and survival. This suggests that GALNT13 may be a potential drug target for the treatment of diseases associated with cell signaling pathways that are not related to the TGF-β or FGF pathways, such as cancer, neurodegenerative diseases, and autoimmune disorders.

GALNT13 is also a unique protein that has been shown to function as a both a protein and a nucleic acid. It consists of 138 amino acids and has a calculated molecular mass of 19.1 kDa. GALNT13 has been shown to have unique functions in cell signaling pathways , including the regulation of cell adhesion, migration, and survival. It is also involved in the regulation of cell signaling pathways that are not related to the TGF-β or FGF pathways, such as cell signaling pathways that are involved in the regulation of cell adhesion, migration, and survival.

GALNT13 has also been shown to have unique functions in cell signaling pathways that are not related to the TGF-β or FGF pathways, such as the regulation of cell signaling pathways that are involved in the regulation of cell adhesion, migration, and survival. It is also involved in the regulation of cell signaling pathways that are not related to the TGF-β or FGF pathways, such as cell signaling pathways that are involved in the regulation of cell adhesion, migration, and survival.

In conclusion, GALNT13 is a unique protein that has been shown to function as a both a protein and a nucleic acid. It is involved in the regulation of cell signaling pathways that are not related to the TGF-β or FGF pathways, including the regulation of cell adhesion, migration, and survival. The unique functions of GALNT13 make it an attractive drug target for the treatment of diseases associated with the TGF-β or FGF pathways, as well as those associated with cell signaling pathways that are not related to these pathways. Further research is needed to fully understand the unique functions of GALNT13 and its potential as a drug target.

Protein Name: Polypeptide N-acetylgalactosaminyltransferase 13

Functions: Catalyzes the initial reaction in O-linked oligosaccharide biosynthesis, the transfer of an N-acetyl-D-galactosamine (GalNAc) residue from UDP-GalNAc to a serine or threonine residue on the protein receptor (PubMed:12407114, PubMed:22186971). Generates GalNAc-O-Ser/Thr structure also known as Tn antigen, which itself is immunogenic but also serves as a precursor for the synthesis of different mucin-type O-glycan core structures (PubMed:12407114). Contributes to the synthesis of O-linked glycans on mucins and proteoglycans of the central nervous system. May promote neurogenesis through glycosylation and stabilization of PDPN (PubMed:12407114, PubMed:22186971) (By similarity)

The "GALNT13 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about GALNT13 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets